Targeted and minimal invasive gene therapy for Machado-Joseph Disease

RNA silencing techniques (e.g. RNAi) targeting single nucleotide polymorphisms (SNPs) in the ataxin-3 mRNA in linkage disequilibrium with the Machado Joseph disease-causing expansion.

Delivery via minimally invasive routes, including intra-cerebrospinal and intravenous administration, using adeno-associated viral vectors (AAVs).

Technology Offer_Gene Therapy for Machado Joseph Disease

We use cookies to improve your visit to our website.